B2M and diffuse large B-cell lymphoma: Besides the genetic characterization of the mutational profile and CNA, the quantification of cfDNA has been associated with well-recognized clinical parameters of tumor burden (LDH, beta-2-microglobulin, total metabolic tumor volume), CR rate, and survival in DLBCL and other lymphoid malignances, including a series from our institution [9,10,12].